CMS to meet on beta amyloid PET imaging reimbursement
The Centers for Medicare & Medicaid Services (CMS) will convene a meeting Jan. 30, 2013, to review available evidence and hear public testimony on the use of beta amyloid PET imaging for the management of dementia and neurodegenerative disease.

The Medicare Evidence Development & Coverage Advisory Committee (MEDCAC) is interested in the clinical impact of this technology on health outcomes experienced by patients, according to the meeting announcement.

Currently, Medicare doesn’t cover beta amyloid PET imaging. Section 220.6 of the National Coverage Determination manual, which addresses coverage of PET, can be found here.